Amino-substituted heteroaryls for treating cancers with EGFR mutations
US12037346B2 · kind B2 · utility
0Cited by
135References
43Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 12, 2022 |
| Grant date | Jul 16, 2024 |
| Priority date | — |
| Expiry date | Apr 12, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed are amino-substituted heteroaromatic compounds such as a compound of Formula (I): pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the amino-substituted heteroaromatic compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.